The Truth behind Three Natural Cancer “Cures”

“The Internet is full of ‘miracle cures’ for cancer and alleged surefire ways to prevent it, and well-meaning people may urge cancer patients to just try them out in hopes of eliminating their disease. Some patients, worried that conventional treatments won’t work or pose significant side effects, seek a treatment whose effectiveness isn’t actually supported by scientific evidence or may even prove dangerous. During a time of uncertainty and anxiety, it’s understandable that any hope for a cure — even if it isn’t medically proven — is tempting.

“ ‘Patients want something “natural” to try to treat their cancer or prevent their cancer from coming back,’ says Memorial Sloan Kettering pharmacist and herbalist K. Simon Yeung. ‘But the people promoting these treatments might not necessarily have a medical or oncology background. In addition, patients who try these therapies may find, when they come back to seek mainstream treatment, that it’s too late and their cancer has already spread.’ “


Medical Marijuana Helpful for Cancer-Linked Symptoms

“Cannabis and cannabinoid pharmaceuticals can be helpful for nausea and vomiting, pain, and weight loss associated with cancer, according to research published online Dec. 10 in CA: A Cancer Journal for Clinicians.

“John L. Kramer, M.D., from the American Cancer Society in Atlanta, reviewed evidence for medical uses of marijuana and cannabinoids.

“Kramer notes that marijuana and cannabinoids are used for nausea and vomiting, pain, and for treatment of poor appetite and weight loss. Cannabinoids may also have a role as antineoplastic agents. More high-quality studies of marijuana and cannabinoid pharmaceuticals are necessary to elucidate the various strains of marijuana and their bioactive compounds. Studies should also explore how best to administer marijuana and its bioactive components; differences are noted in pharmacokinetics between oral ingestion and inhalation and there may be variations in clinical effect for different indications. For example, inhalation may be better for treatment of nausea and vomiting. However, smoked marijuana contains carcinogens, and may cause injury to lungs. Marijuana also has acute effects on neuropsychiatric test performance.”


Further Evidence that Cannabis Reduces Tumor Growth in New Study

illustration of cancer cells“The main psychoactive ingredient in cannabis – tetrahydrocannabinol – could be used to reduce tumor growth in cancer patients, according to an international research team.”

“Previous studies have suggested that cannabinoids, of which tetrahydrocannabinol (THC) is one, have anti-cancer properties. In 2009, researchers at Complutense University in Spain found that THC induced the death of brain cancer cells in a process known as ‘autophagy.’

“The researchers found that administering THC to mice with human tumors initiated autophagy and caused the growth of the tumors to decrease. Two human patients with highly aggressive brain tumors who received intracranial administration of THC also showed similar signs of autophagy, upon analysis.

“The team behind the new study – co-led by Complutense University and the University of Anglia (UEA) in the UK – claims to have discovered previously unknown ‘signaling platforms’ that allow THC to shrink tumors.”


GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA in Cancer Pain

“Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to Sativex® for the treatment of pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy. Sativex is currently in Phase 3 clinical trials for this indication.

FDA’s Fast Track program facilitates the development of drugs intended to treat serious or life‑threatening conditions and that have the potential to address unmet medical needs. A drug program with Fast Track status is afforded greater access to the FDA for the purpose of expediting the drug’s development, review and potential approval.”


GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA in Cancer Pain

“Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to Sativex® for the treatment of pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy. Sativex is currently in Phase 3 clinical trials for this indication.

FDA’s Fast Track program facilitates the development of drugs intended to treat serious or life‑threatening conditions and that have the potential to address unmet medical needs. A drug program with Fast Track status is afforded greater access to the FDA for the purpose of expediting the drug’s development, review and potential approval.”


GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA in Cancer Pain

“Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to Sativex® for the treatment of pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy. Sativex is currently in Phase 3 clinical trials for this indication.

FDA’s Fast Track program facilitates the development of drugs intended to treat serious or life‑threatening conditions and that have the potential to address unmet medical needs. A drug program with Fast Track status is afforded greater access to the FDA for the purpose of expediting the drug’s development, review and potential approval.”